Amgen Spiking Lower 1.5%, Says Primary Endpoint of Durable Response Rate Met in Phase 3 Study of Talimogene, Secondary Endpoint Not Met

Amgen Spiking Lower 1.5%, Says Primary Endpoint of Durable Response Rate Met in Phase 3 Study of Talimogene, Secondary Endpoint Not Met

Submitted by admin on April 4, 2014 - 9:14am
Source: 
Yahoo/Benzinga
News Tags: 
Amgen
Talimogene Laherparepvec
melanoma
Headline: 
Amgen Spiking Lower 1.5%, Says Primary Endpoint of Durable Response Rate Met in Phase 3 Study of Talimogene, Secondary Endpoint Not Met

Do Not Allow Advertisers to Use My Personal information